Therapeutic areas graphic
87% Project Managers
have oncology experience

Imagine hassle-free oncology clinical trials

Moving your studies forward around the world.

PSI’s key differentiator is our ability to plan and execute complex clinical trials on time, saving our customers millions of development dollars..

Predictable patient enrollment is a key measure of success.

  • PSI works with hundreds of sites in six continents in a variety of oncological indications.
  • 87% of our Project Managers and 71% of our CRAs have oncology experience.
  • PSI aced multiple FDA and EMA inspections resulting in drug approvals in breast, lung, prostate, colorectal, renal, pancreatic cancers, as well as various types of supportive care.

The global pipeline for oncology R&D remains impressive. Hundreds of molecules are now in late-stage development all over the world holding promise for vast unmet needs. The pipeline of oncology drugs in clinical development has expanded by 45% over the past ten years. The majority of late-stage pipeline is represented by targeted therapies which include small molecule protein kinase inhibitors and monoclonal antibodies, as well as cancer vaccines for a wide variety of tumor types.

Clinical trials in oncology have become significantly more complex. As more oncogenic driver mutations are identified, patient populations often have to be more segmented based on biomarker status coming from complex diagnostic evaluations. Different segments within major cancer types, such as lung, colorectal or melanoma, are taking advantage of targeted medicines, which are currently being extensively tested. There is no end, it seems, to further narrowing of patients’ populations, as new pharmaceutical classes emerge, often going hand in hand with novel companion diagnostics. There is no universal recipe for a successful trial, every research study requires individual approach to feasibility based on disease epidemiology, standards of care, specifics of drug logistics, and many other consideration.

 

Meet the global clinical research organization ranked No. 1.

“It was wonderful working with PSI. No other CRO is as productive and professional. I hope I get the chance to work with you again.” Chief Medical Officer, UK

Your unfair advantage

Ranked #1 Global CRO by Investigators Worldwide

Ranked #1 Global CRO by Investigators
Worldwide. CenterWatch 2015-2017

Therapeutic areas

Other therapeutic areas of expertise